Massachusetts Financial Services Co. MA Purchases 107,348 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Massachusetts Financial Services Co. MA grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,267,375 shares of the biopharmaceutical company's stock after acquiring an additional 107,348 shares during the period. Massachusetts Financial Services Co. MA owned about 1.09% of Amicus Therapeutics worth $30,779,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of FOLD. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics during the 3rd quarter worth approximately $55,000. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the last quarter. XTX Topco Ltd bought a new position in Amicus Therapeutics during the third quarter worth $405,000. Geode Capital Management LLC increased its holdings in shares of Amicus Therapeutics by 1.2% in the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company's stock valued at $70,499,000 after purchasing an additional 80,926 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Amicus Therapeutics in the third quarter valued at $702,000.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.75.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock traded down $0.03 during mid-day trading on Friday, reaching $6.48. 3,810,888 shares of the company were exchanged, compared to its average volume of 2,600,124. The firm has a market cap of $1.99 billion, a PE ratio of -36.00, a PEG ratio of 1.51 and a beta of 0.79. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company has a fifty day simple moving average of $8.71 and a 200-day simple moving average of $9.65. Amicus Therapeutics, Inc. has a 12 month low of $6.20 and a 12 month high of $12.65.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.